Mark Cuban Cost Plus Drug Co. has added Vegzelma, a biosimilar indicated for six cancer types, to its marketplace for hospitals and other healthcare providers.  The company plans to expand its biosimilar offerings amid growing demand for biologics among health…

The Pennsylvania House passed legislation Dec. 16 to preserve access to pharmacist-administered vaccines, even if federal recommendations change. The bill would allow pharmacists to provide vaccines based on guidance from state authorities — including the Pennsylvania Department of Health and…

All community and independent pharmacies in the Optum Rx network have transitioned to a cost-based reimbursement model aimed at improving payment transparency and stability. The shift follows new agreements with three pharmacy services administration organizations, which represent more than 17,000…

The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized trial of 405 patients who had progressed on prior androgen receptor pathway…

Some U.S. hospitals and health systems are marking up generic cancer drugs by more than five times their commercial rates, Bloomberg reported Dec. 17. Bloomberg analyzed data from the price transparency platform Turquoise Health. Of the more than 1,700 hospitals and eight…

Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker.  CagriSema is a weekly injection of semaglutide, a GLP-1, and cagrilintide, a long-acting amylin…

After a UCI Health pharmacy pilot exceeded its goal $1.1 million in gross margin by an additional $300,000, the Orange, Calif.-based system approved a $30 million expansion of the project.  Melanie Joe, PharmD, chief pharmacy officer at UCI Health, a…

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients ages 12 and older. The approval is based on data from the drugmaker’s SWIFT-1 and SWIFT-2 trials, which showed…

The FDA approved a label change for Pfizer’s birth control injection Depo-Provera on Dec. 13, adding a warning about the risk of meningioma — a brain tumor — to two versions of the drug. The update applies to Depo-Provera CI…

Healthcare is continuously evolving. And with that comes increasing complexity – fragmented care, staffing challenges, cybersecurity concerns, inventory visibility gaps, and regulatory pressures, just to name a few. Today’s systems can create silos across the care continuum, keeping pharmacists and…